Trials / Completed
CompletedNCT03873883
First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer
Phase I/Ib First-in-Human Study of EOS100850 (Inupadenant) As a Single Agent and in Combination with Pembrolizumab And/or Chemotherapy in Participants with Advanced Cancers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 119 (actual)
- Sponsor
- iTeos Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 (Inupadenant) as a Single Agent and in Combination with Pembrolizumab and/or Chemotherapy in Participants with Advanced Cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EOS100850 | Oral administration |
| DRUG | Pembrolizumab | IV Infusion |
| DRUG | Chemotherapy | Standard of Care IV Infusion |
Timeline
- Start date
- 2019-02-05
- Primary completion
- 2024-05-28
- Completion
- 2024-05-28
- First posted
- 2019-03-14
- Last updated
- 2024-09-19
Locations
19 sites across 6 countries: United States, Belgium, France, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03873883. Inclusion in this directory is not an endorsement.